Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Increasing Use Of Data Mining To Detect Early Safety Signals

Executive Summary

FDA is making increased use of data mining software to identify early drug safety signals in its adverse event database, Office of Pharmacoepidemiology & Statistical Science Director Paul Seligman said

You may also be interested in...



PhRMA Aims To Clarify Use Of AERS Signals Through Data Mining Studies

While all sources of reports to FDA's Adverse Event Reporting System make significant contributions to signal detection, foreign sources appear to be one of the strongest contributors, preliminary results from a PhRMA-sponsored study of the database suggest

PhRMA Aims To Clarify Use Of AERS Signals Through Data Mining Studies

While all sources of reports to FDA's Adverse Event Reporting System make significant contributions to signal detection, foreign sources appear to be one of the strongest contributors, preliminary results from a PhRMA-sponsored study of the database suggest

Adverse Event Analysis Could Leap Forward With New Statistical Techniques

Data mining the FDA Adverse Event Reporting System could take a leap forward as researchers validate a new statistical algorithm and publish results later this year

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel